Locations:
Search
Tumor genomics offer clues for identifying high risk of relapse
Blinatumomab followed by POMP maintenance shows effectiveness for newly diagnosed patients
Study to test efficacy of immunotherapy with chemotherapy and radiation
Molecular targets may offer noncytotoxic treatment path
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Will avelumab plus cabozatinib outperform avelumab monotherapy as maintenance treatment?
A New Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
Improving safety, efficacy and access for emerging therapies
Phase 2 study of parsaclisib with ruxolitinib demonstrates improved efficacy for patients previously treated with ruxolitinib alone
DESTINY-Breast04 study leads to practice-changing findings
Largest real-world cohort of polycythemia vera patients
Advertisement
Advertisement